LetterHypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma
References (9)
- et al.
Hypersensitivity reactions to cisplatin and carboplatin—a report of six cases
Ann Oncol
(1992) - et al.
A multicenter phase II study of carboplatin in advanced ovarian carcinoma: final report
Ann Oncol
(1992) - et al.
Allergic reactions to carboplatin
Ann Oncol
(1992) - et al.
Respiratory allergy caused by platinum salts
J Allergy
(1968)
Cited by (61)
Outpatient desensitization in selected patients with platinum hypersensitivity reactions
2017, Gynecologic OncologyCitation Excerpt :Once workers developed these symptoms, they were always symptomatic in platinum-containing environments; however, it was also noted that patients could be systematically desensitized. It has been postulated that HSR are type I, immunoglobin E (IgE) mediated hypersensitivity reactions [16]. In type I hypersensitivity reactions, IgE bound to mast cells and basophils become activated causing cross-linking of the IgE ultimately resulting in release of pharmacologically active mediators including histamine, leukotrienes and prostaglandins [8].
Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin
2017, Gynecologic OncologyCitation Excerpt :About 70% of patients with a platinum sensitive recurrence are rechallenged with a carboplatin-based regimen and a considerable amount of patients receiving carboplatin will eventually experience an HSR [2–4]. Several studies have tried to determine typical HSR patterns of presentation and related risk factors [6–17]; however, mechanisms underlying such reactions are still poorly understood, even if both an immediate type IgE mediated hypersensitivity reaction and a direct action of platinum on mast cells, leading to the release of vasoactive substances, are thought to play a relevant role. The risk of developing HSR has been reported to increase with the number of carboplatin lines and is estimated to be < 1% during first line, and as high as 27% in patients treated with more than seven cycles of therapy.
Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial
2011, Gynecologic OncologyCitation Excerpt :The global rate of hypersensitivity (24.6%) observed in the CALYPSO trial is consistent with that reported in the literature for the combinations as well as with that observed in studies of retreatment with single-agent carboplatin [22–26]. In the rechallenge setting, the incidence of carboplatin HSRs can exceed 20% [20,27]. Hence, a number of researchers have attempted to investigate predictive factors to identify patients who are likely to develop hypersensitivity [7,9,16,20,21,28–30].
Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherapy: a Literature Review
2022, Clinical Reviews in Allergy and ImmunologyAntitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA -mutated, high-grade ovarian cancer, and an update on safety
2019, International Journal of Gynecological Cancer